The African psychoactive alkaloid Ibogaine, Schedule 1 in the USA, researched for substance use since the 1950’s, has demonstrated effectiveness in reversing tolerance & craving for opioids, stimulants & alcohol. Risks & fatalities are involved, due to the demographic, screening, inducing bradycardia, prolonging the QT interval & blocking the Potassium hERG channel, further complicated by opioid maintenance medications & psychiatric drugs. Almost all ibogaine centres, rapidly increasing in ...
Dana Beal – Nerve Growth Factor GDNF Elucidates Ibogaine’s Persistence & Immune Modulatory Effects
Ibogaine shares receptor effects with both Salvia divinorum (κ-opiate down-regulation of tolerance via beta-arrestin) and with ketamine (NMDA antagonism, curbing narcotic withdrawal and super-sensitization to stimulants). Additionally, ibogaine induces the nerve growth factor GDNF (Glia-Derived Neurotrophic Factor), re-sprouting chronically desensitised dopamine receptors and replacing the neural deficit experienced as craving. Moreover, the 10-fold GDNF spike engendered by ibogaine back-signals to cell nuclei to make more GDNF, setting ...
Ibogaine influence on gene expression – Roman Paskulin
Tabernanthe iboga with its alkaloid ibogaine is recognized in the West as a remedy against diverse addictions, while traditionally it is used as inductor of maturation. Its uniqueness lays in the multiple actions – it triggers psychedelic insights, facilitates metabolic adaptations and sets new ...
Ignacio Carrera: Ibogaine & Neurotrophic Factors: GDNF, BDNF, and NGF Releasing Properties
Learn more and donate: http://www.maps.org/
Ignacio Carrera, PhD
Ibogaine and Neurotrophic Factors: GDNF, BDNF,
and NGF Releasing Properties of Ibogaine and Activity
of Novel Ibogaine Analogues
2017 Psychedelic Science Conference
http://psychedelicscience.org/
A six-day global gathering of the international scientific community in Oakland, California to explore new research into the benefits and risks of MDMA, LSD, psilocybin, ayahuasca, ketamine, ibogaine, medical marijuana, and more.
source
Panel: Insights from Contemporary Ibogaine Addiction Research w/ Noller & Brown
Learn more and donate: http://www.maps.org/
PANEL:
Geoff Noller, PhD, and Thomas Kingsley Brown, PhD
moderated by Clare Wilkins
Insights from Contemporary
Ibogaine Research for Addiction
2017 Psychedelic Science Conference
http://psychedelicscience.org/
A six-day global gathering of the international scientific community in Oakland, California to explore new research into the benefits and risks of MDMA, LSD, psilocybin, ayahuasca, ketamine, ibogaine, medical marijuana, and more.
source